Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data

Author: Michael Baudis

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Chromosomal abnormalities have been associated with most human malignancies, with gains and losses on some genomic regions associated with particular entities.

Methods

Of the 15429 cases collected for the Progenetix molecular-cytogenetic database, 5918 malignant epithelial neoplasias analyzed by chromosomal Comparative Genomic Hybridization (CGH) were selected for further evaluation. For the 22 clinico-pathological entities with more than 50 cases, summary profiles for genomic imbalances were generated from case specific data and analyzed.

Results

With large variation in overall genomic instability, recurring genomic gains and losses were prominent. Most entities showed frequent gains involving 8q2, while gains on 20q, 1q, 3q, 5p, 7q and 17q were frequent in different entities. Loss "hot spots" included 3p, 4q, 13q, 17p and 18q among others. Related average imbalance patterns were found for clinically distinct entities, e.g. hepatocellular carcinomas (ca.) and ductal breast ca., as well as for histologically related entities (squamous cell ca. of different sites).

Conclusion

Although considerable case-by-case variation of genomic profiles can be found by CGH in epithelial malignancies, a limited set of variously combined chromosomal imbalances may be typical for carcinogenesis. Focus on the respective regions should aid in target gene detection and pathway deduction.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Speicher MR, Gwyn Ballard S, Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet. 1996, 12: 368-375. 10.1038/ng0496-368.CrossRefPubMed
4.
Veldman T, Vignon C, Schrock E, Rowley JD, Ried T: Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet. 1997, 15: 406-410. 10.1038/ng0497-406.CrossRefPubMed
5.
Cremer T, Lichter P, Borden J, Ward DC, Manuelidis L: Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes. Hum Genet. 1988, 80: 235-246. 10.1007/BF01790091.CrossRefPubMed
6.
Lichter P, Cremer T, Borden J, Manuelidis L, Ward DC: Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. Hum Genet. 1988, 80: 224-234. 10.1007/BF01790090.CrossRefPubMed
7.
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992, 5083: 818-821. 10.1126/science.1359641.CrossRef
8.
Joos S, Scherthan H, Speicher MR, Schlegel J, Cremer T, Lichter P: Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Hum Genet. 1993, 90 (6): 584-589. 10.1007/BF00202475.CrossRefPubMed
9.
Bentz M, Plesch A, Stilgenbauer S, Dohner H, Lichter P: Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer. 1998, 2: 172-175. 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T.CrossRef
10.
Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P: Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer. 1997, 4: 399-407. 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I.CrossRef
11.
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998, 2: 207-211. 10.1038/2524.CrossRef
12.
Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999, 1: 41-46.
13.
Nowell PC, Hungerford DA: A minute chromosome in chronic granulocytic leukemia. Science. 1960, 132: 1497-
14.
Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 5405: 290-293. 10.1038/243290a0.CrossRef
15.
Manolov G, Manolova Y: Marker band in one chromosome 14 from Burkitt lymphomas. Nature. 1972, 237: 33-34. 10.1038/237033a0.CrossRefPubMed
16.
Mrozek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev. 2004, 18: 115-136. 10.1016/S0268-960X(03)00040-7.CrossRefPubMed
17.
18.
Speicher MR, du Manoir S, Schrock E, Holtgreve-Grez H, Schoell B, Lengauer C, Cremer T, Ried T: Molecular cytogenetic analysis of formalin-fixed, paraffin-embedded solid tumors by comparative genomic hybridization after universal DNA-amplification. Hum Mol Genet. 1993, 11: 1907-1914. 10.1093/hmg/2.11.1907.CrossRef
19.
Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V, Zhu Y: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998, 152: 1107-1123.PubMedPubMedCentral
20.
Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, Zhu Y: DNA copy number losses in human neoplasms. Am J Pathol. 1999, 155: 683-694.CrossRefPubMedPubMedCentral
21.
Gebhart E, Liehr T: Patterns of genomic imbalances in human solid tumors (Review). Int J Oncol. 2000, 16: 383-399.PubMed
22.
Gebhart E: Genomic imbalances in human leukemia and lymphoma detected by comparative genomic hybridization (Review). Int J Oncol. 2005, 27: 593-606.PubMed
23.
Struski S, Doco-Fenzy M, Cornillet-Lefebvre P: Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet. 2002, 135: 63-90. 10.1016/S0165-4608(01)00624-0.CrossRefPubMed
24.
Myllykangas S, Himberg J, Bohling T, Nagy B, Hollmen J, Knuutila S: DNA copy number amplification profiling of human neoplasms. Oncogene. 2006, 25: 7324-7332. 10.1038/sj.onc.1209717.CrossRefPubMed
25.
26.
Baudis M, Cleary ML: Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics. 2001, 12: 1228-1229. 10.1093/bioinformatics/17.12.1228.CrossRef
27.
Baudis M: Online database and bioinformatics toolbox to support data mining in cancer cytogenetics. Biotechniques. 2006, 40 (3): 269-272.CrossRefPubMed
28.
Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, Kestler HA, Haslinger C, Stilgenbauer S, Dohner H, Bentz M, Lichter P: Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA. 2004, 4: 1039-1044. 10.1073/pnas.0304717101.CrossRef
29.
International Classification of Diseases for Oncology (ICD-O), Edition. World Health Organization. Edited by: Fritz A, Percy C, Jack A, Sobin LH, Parkin MD. 2000, Geneva, Third
30.
Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, Storkel S, Kovacs A, Kovacs G: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994, 145: 356-364.PubMedPubMedCentral
31.
Wild P, Giedl J, Stoehr R, Junker K, Boehm S, van Oers J, Zwarthoff E, Blaszyk H, Fine S, Humphrey P, Dehner L, Amin M, Epstein J, Hartmann A: Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. J Pathol. 2006
32.
Clausen OP, Aass HC, Beigi M, Purdie KJ, Proby CM, Brown VL, Mattingsdal M, Micci F, Kolvraa S, Bolund L, Deangelis PM: Are Keratoacanthomas Variants of Squamous Cell Carcinomas? A Comparison of Chromosomal Aberrations by Comparative Genomic Hybridization. J Invest Dermatol. 2006
33.
van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FB, van't Veer LJ, Nederlof PM: Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 2005, 65: 822-827.PubMed
34.
35.
36.
37.
38.
39.
40.
Vos CB, ter Haar NT, Rosenberg C, Peterse JL, Cleton-Jansen AM, Cornelisse CJ, van de Vijver MJ: Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer. 1999, 81: 1410-1418. 10.1038/sj.bjc.6693372.CrossRefPubMedPubMedCentral
41.
Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG: Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer. 2006, 6: 96-10.1186/1471-2407-6-96.CrossRefPubMedPubMedCentral
42.
Aubele M, Auer G, Braselmann H, Nahrig J, Zitzelsberger H, Quintanilla-Martinez L, Smida J, Walch A, Hofler H, Werner M: Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol. 2002, 24: 77-87.CrossRefPubMedPubMedCentral
43.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
44.
Barlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O, Kallioniemi A: Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer. 1997, 20: 372-376. 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z.CrossRefPubMed
45.
Mattfeldt T, Wolter H, Kemmerling R, Gottfried HW, Kestler HA: Cluster analysis of comparative genomic hybridization (CGH) data using self-organizing maps: application to prostate carcinomas. Anal Cell Pathol. 2001, 23 (1): 29-37.CrossRefPubMedPubMedCentral
46.
Ribeiro FR, Jeronimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA, Teixeira MR: 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res. 2006, 12: 3961-3970. 10.1158/1078-0432.CCR-05-1977.CrossRefPubMed
47.
Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schroder FH, Tanke HJ, van Dekken H: Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol. 2001, 158: 399-406.CrossRefPubMedPubMedCentral
48.
Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J: DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007, 67: 692-700. 10.1002/pros.20543.CrossRefPubMed
49.
van Grieken NC, Weiss MM, Meijer GA, Hermsen MA, Scholte GH, Lindeman J, Craanen ME, Bloemena E, Meuwissen SG, Baak JP, Kuipers EJ: Helicobacter pylori-related and -non-related gastric cancers do not differ with respect to chromosomal aberrations. J Pathol. 2000, 192: 301-306. 10.1002/1096-9896(2000)9999:9999<::AID-PATH697>3.0.CO;2-F.CrossRefPubMed
50.
Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, Brannstrom M, Horvath G: Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet. 2006, 167: 103-108. 10.1016/j.cancergencyto.2006.01.009.CrossRefPubMed
51.
Partheen K, Levan K, Osterberg L, Helou K, Horvath G: Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer. 2004, 40: 342-348. 10.1002/gcc.20053.CrossRefPubMed
52.
Ghadimi BM, Grade M, Liersch T, Langer C, Siemer A, Fuzesi L, Becker H: Gain of chromosome 8q23-24 is a predictive marker for lymph node positivity in colorectal cancer. Clin Cancer Res. 2003, 9: 1808-1814.PubMed
53.
De Angelis PM, Stokke T, Beigi M, Flatberg G, Enger M, Haug K, Aass HC, Schjolberg A, Andresen PA, Ariansen S, Bo AS, Mjaland O, Clausen OP: Chromosomal 20q gain in the DNA diploid component of aneuploid colorectal carcinomas. Int J Cancer. 2007
54.
Grade M, Becker H, Liersch T, Ried T, Ghadimi BM: Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell Oncol. 2006, 28: 71-84.PubMedPubMedCentral
55.
Terracciano L, Tornillo L: Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. Pathologica. 2003, 95: 71-82.PubMed
56.
Steinemann D, Skawran B, Becker T, Tauscher M, Weigmann A, Wingen L, Tauscher S, Hinrichsen T, Hertz S, Flemming P, Flik J, Wiese B, Kreipe H, Lichter P, Schlegelberger B, Wilkens L: Assessment of differentiation and progression of hepatic tumors using array-based comparative genomic hybridization. Clin Gastroenterol Hepatol. 2006, 4: 1283-1291. 10.1016/j.cgh.2006.07.010.CrossRefPubMed
57.
Lau SH, Guan XY: Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol Sin. 2005, 26: 659-665. 10.1111/j.1745-7254.2005.00126.x.CrossRefPubMed
58.
Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, Cardesa A: PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res. 1994, 54: 4813-4817.PubMed
59.
Richter H, Braselmann H, Hieber L, Thomas G, Bogdanova T, Tronko N, Zitzelsberger H: Chromosomal imbalances in post-chernobyl thyroid tumors. Thyroid. 2004, 14: 1061-1064. 10.1089/thy.2004.14.1061.CrossRefPubMed
60.
Chen X, Knauf JA, Gonsky R, Wang M, Lai EH, Chissoe S, Fagin JA, Korenberg JR: From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. Am J Hum Genet. 1998, 63: 625-637. 10.1086/301973.CrossRefPubMedPubMedCentral
61.
Schulte KM, Niederacher D, An HX, Staudt S, Simon D, Beckmann MW, Goretzki PE: INT-2 gene amplification in differentiated human thyroid cancer. Exp Clin Endocrinol Diabetes. 1996, 104 (Suppl 4): 101-104.CrossRefPubMed
62.
Yakut T, Schulten HJ, Demir A, Frank D, Danner B, Egeli U, Gebitekin C, Kahler E, Gunawan B, Urer N, Ozturk H, Fuzesi L: Assessment of molecular events in squamous and non-squamous cell lung carcinoma. Lung Cancer. 2006, 54: 293-301. 10.1016/j.lungcan.2006.08.011.CrossRefPubMed
63.
Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, Narayan G, Schneider A, Terry MB, Murty VV: Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer. 2004, 4: 5-10.1186/1471-2407-4-5.CrossRefPubMedPubMedCentral
64.
Koon N, Zaika A, Moskaluk CA, Frierson HF, Knuutila S, Powell SM, El-Rifai W: Clustering of molecular alterations in gastroesophageal carcinomas. Neoplasia. 2004, 6: 143-149. 10.1593/neo.03385.CrossRefPubMedPubMedCentral
65.
Bentz M, Bergerheim US, Li C, Joos S, Werner CA, Baudis M, Gnarra J, Merino MJ, Zbar B, Linehan WM, Lichter P: Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenet Cell Genet. 1996, 75 (1): 17-21.CrossRefPubMed
66.
Hoglund M, Gisselsson D, Soller M, Hansen GB, Elfving P, Mitelman F: Dissecting karyotypic patterns in renal cell carcinoma: an analysis of the accumulated cytogenetic data. Cancer Genet Cytogenet. 2004, 153: 1-9. 10.1016/j.cancergencyto.2003.12.019.CrossRefPubMed
67.
Li X, Wang E, Zhao YD, Ren JQ, Jin P, Yao KT, Marincola FM: Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic hybridization results. J Transl Med. 2006, 4: 4-10.1186/1479-5876-4-4.CrossRefPubMedPubMedCentral
68.
Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q: The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 2007, 26: 934-944. 10.1038/sj.onc.1209839.CrossRefPubMed
69.
El-Rifai W, Kamel D, Larramendy ML, Shoman S, Gad Y, Baithun S, El-Awady M, Eissa S, Khaled H, Soloneski S, Sheaff M, Knuutila S: DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer. Am J Pathol. 2000, 156: 871-878.CrossRefPubMedPubMedCentral
70.
Duerr EM, Chung DC: Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2007, 21: 1-14. 10.1016/j.beem.2006.12.001.CrossRefPubMed
71.
Bauer J, Bastian BC: [DNA copy number changes in the diagnosis of melanocytic tumors]. Pathologe. 2007
72.
Karhu R, Mahlamaki E, Kallioniemi A: Pancreatic adenocarcinoma – genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer. 2006, 45: 721-730. 10.1002/gcc.20337.CrossRefPubMed
73.
Lee JY, Park YN, Uhm KO, Park SY, Park SH: Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization. J Korean Med Sci. 2004, 19: 682-687.CrossRefPubMedPubMedCentral
74.
Coe BP, Lee EH, Chi B, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL: Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines. Genes Chromosomes Cancer. 2006, 45: 11-19. 10.1002/gcc.20260.CrossRefPubMed
75.
Levan K, Partheen K, Osterberg L, Helou K, Horvath G: Chromosomal alterations in 98 endometrioid adenocarcinomas analyzed with comparative genomic hybridization. Cytogenet Genome Res. 2006, 115: 16-22. 10.1159/000094796.CrossRefPubMed
76.
Bryndorf T, Kirchhoff M, Larsen J, Andreasson B, Bjerregaard B, Westh H, Rose H, Lundsteen C: The most common chromosome aberration detected by high-resolution comparative genomic hybridization in vulvar intraepithelial neoplasia is not seen in vulvar squamous cell carcinoma. Cytogenet Genome Res. 2004, 106: 43-48. 10.1159/000078559.CrossRefPubMed
77.
Burnworth B, Popp S, Stark HJ, Steinkraus V, Brocker EB, Hartschuh W, Birek C, Boukamp P: Gain of 11q/cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation. Oncogene. 2006, 25: 4399-4412. 10.1038/sj.onc.1209474.CrossRefPubMed
78.
Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet. 1993, 4: 138-141. 10.1016/0168-9525(93)90209-Z.CrossRef
79.
Seruca R, Suijkerbuijk RF, Gartner F, Criado B, Veiga I, Olde-Weghuis D, David L, Castedo S, Sobrinho-Simoes M: Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genet Cytogenet. 1995, 82: 140-145. 10.1016/0165-4608(95)00033-L.CrossRefPubMed
80.
Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, Offit K, Chaganti RS: REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood. 1996, 87: 25-29.PubMed
81.
Perry A, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, Feuerstein BG, Jenkins RB, Carson DA: Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol. 1997, 56: 999-1008.CrossRefPubMed
82.
Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter P: Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer. 1998, 23: 307-316. 10.1002/(SICI)1098-2264(199812)23:4<307::AID-GCC5>3.0.CO;2-#.CrossRefPubMed
83.
Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S, Mechtersheimer G, Trumper L, Moller P, Lichter P, Barth TF: Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002, 99: 1381-1387. 10.1182/blood.V99.4.1381.CrossRefPubMed
84.
Penzel R, Hoegel J, Schmitz W, Blaeker H, Morresi-Hauf A, Aulmann S, Hecker E, Mechtersheimer G, Otto HF, Rieker RJ: Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer. 2003, 105: 494-498. 10.1002/ijc.11101.CrossRefPubMed
85.
Liu J, Mohammed J, Carter J, Ranka S, Kahveci T, Baudis M: Distance-based clustering of CGH data. Bioinformatics. 2006, 22: 1971-1978. 10.1093/bioinformatics/btl185.CrossRefPubMed
86.
Liu J, Ranka S, Kahveci T: Markers improve clustering of CGH data. Bioinformatics. 2007, 23: 450-457. 10.1093/bioinformatics/btl624.CrossRefPubMed
Metadata
Title
Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data
Author
Michael Baudis
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-226

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Correlation between the progressive cytoplasmic expression of a novel small heat shock protein (Hsp16.2) and malignancy in brain tumors

Research article

Origin and distribution of the BRCA2-8765delAG mutation in breast cancer

Research article

A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium

Research article

Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells

Research article

Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells

Research article

Deficiency of G1 regulators P53, P21Cip1and/or pRb decreases hepatocyte sensitivity to TGFβ cell cycle arrest
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits